Back to Search
Start Over
Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib
- Source :
- Critical reviews in oncology, hematology, CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, Critical Reviews in Oncology/Hematology, Vol. 169, no./, p. 103564 (2022)
- Publication Year :
- 2022
-
Abstract
- Fusions of NTRK (neurotrophic tyrosine receptor kinase) genes with 5' partner genes can result in the expression of chimeric proteins that drive oncogenesis through ligand-independent kinase activation. Despite variable frequencies of NTRK fusions in different tumor types, the fact that they are common to a wide range of cancers raises the possibility of developing tumor-agnostic treatments specifically targeting NTRK fusion products, irrespective of tumor type. The first-generation Trk (tropomyosin receptor kinase) inhibitor, larotrectinib, was the first tumor-agnostic treatment of NTRK fusion-positive cancers in adults and children, to be approved in the European Union. This consensus, developed by a Belgian multidisciplinary expert panel, aims to highlight the unmet medical need associated to NTRK fusion-driven cancer treatment and, based on current knowledge of NTRK fusions and larotrectinib treatment outcome and safety, provide comprehensive guidance to oncologists regarding NTRK fusion-driven cancer diagnostics and the best use of larotrectinib in real-world clinical settings. Larotrectinib; NTRK gene fusion; Trk inhibitor; Tumor-agnostic; Expert opinion; Oncogene proteins; Protein kinase inhibitors.
- Subjects :
- Adult
TRK
Consensus
Oncogene Proteins, Fusion
CANCERS
Oncogene Proteins
Protein kinase inhibitors
medicine.disease_cause
Fusion gene
Belgium
Neoplasms
FIBROSARCOMA
Medicine and Health Sciences
Tumor-agnostic
Humans
media_common.cataloged_instance
Medicine
European union
Child
Protein Kinase Inhibitors
Larotrectinib
media_common
Kinase
business.industry
Cancer
Hematology
Oncogene proteins
EFFICACY
medicine.disease
Fusion protein
Pyrimidines
Oncology
Expert opinion
Trk inhibitor
Trk receptor
NTRK gene fusion
Cancer research
Pyrazoles
Human medicine
Gene Fusion
business
Carcinogenesis
Subjects
Details
- Language :
- English
- ISSN :
- 10408428 and 18790461
- Database :
- OpenAIRE
- Journal :
- Critical reviews in oncology, hematology
- Accession number :
- edsair.doi.dedup.....79a14f49fb02a9bcea364542f5f52347